Head, Prostate Cancer Section and Director, Center for Interventional Oncology
National Cancer Institute, National Institutes of Health
Peter A. Pinto, M.D. is the Director of the Center for Interventional Oncology at the National Institutes of Health, a Tenured Principal Investigator, Senior Urologic Surgeon, Head of the Prostate Cancer Section and Society of Urologic Surgery Fellowship Director in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Maryland. Dr. Pinto is actively involved in efforts to recruit patients into clinical trials researching prostate cancer and to recruit patients for interventional oncology trials to the NCI - NIH. Dr. Pinto’s translational research interests include vaccine strategies and molecularly-targeted therapeutic approaches to modulate cancer cell growth and survival, delineating the metabolomic pathways of cancer, imaging and targeted registration of solid tumors to improve diagnosis and treatment, and the minimally invasive treatment of cancer, including laparoscopic/robotic surgery and focal therapy such as laser ablation, cryotherapy, radiofrequency ablation, irreversible electroporation, high intensity focused ultrasound and implantable drugs. He is nationally and internationally recognized as an expert in the field of prostate cancer and image guidance. He holds multiple patents in the novel method and system of performing MRI guided biopsies and was the co-creator of the UroNav MRI-TRUS fusion prostate biopsy device. Dr. Pinto is protocol chair and / or principal investigator of several NIH protocols investigating methods to improve the detection and treatment of solid tumors with an emphasis on localized and locally advanced prostate cancer. His work has resulted in landmark publications in Journal of the American Medical Association (JAMA) and New England Journal of Medicine (NEJM) helping to establish new American Urological Association / Society of Urologic Oncology Early Detection of Prostate Cancer Guidelines resulting in a new standard of care method to diagnose clinically significant prostate cancer.
Disclosure information not submitted.
Sunday, April 30, 2023
11:00 AM – 11:15 AM CST